Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Esoterix

Premium

Illumina has lowered the price of its Oligator oligo-synthesis technology to $.11 per base from $.16 per base, the company said last week. The new pricing schedule will affect labs “consuming large volumes” of oligonucleotides, Illumina said, although the company did not elaborate further. The Oligator technology, which is used in genotyping, sequencing, gene-expression analysis, and PCR, can produce more than 3,000 oligos at a time, according to the company.


Esoterix has launched a new hepatitis C assay, the HCVExact, which measures virus levels in HCV patients. The assay uses the TaqMan real-time PCR. The company has also released a mutation-anal-ysis test for cystic fibrosis screening. This test, the CFDetx, includes the 25 mutations recommended by both the American College of Medical Genetics and the American College of Obstetricians and Gynecologists for inclusion in HCV assays, Eso-terix said.

Filed under

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.